Silk Road Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.7 Mil. Silk Road Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $75.6 Mil. Silk Road Medical's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $151.2 Mil.
Silk Road Medical's debt to equity for the quarter that ended in Dec. 2023 was 0.51.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Silk Road Medical's Debt-to-Equity or its related term are showing as below:
SILK'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.33 Med: 0.47 Max: 0.64
Current: 0.51
During the past 7 years, the highest Debt-to-Equity Ratio of Silk Road Medical was 0.64. The lowest was -0.33. And the median was 0.47.
Silk Road Medical Debt-to-Equity Historical Data
The historical data trend for Silk Road Medical's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Silk Road Medical Annual Data
|
|
Trend |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
0.64 |
0.46 |
0.63 |
0.47 |
0.51 |
|
Silk Road Medical Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.47 |
0.49 |
0.49 |
0.50 |
0.51 |
Competitive Comparison
For the Medical Devices subindustry, Silk Road Medical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Silk Road Medical Debt-to-Equity Distribution
For the Medical Devices & Instruments industry and Healthcare sector, Silk Road Medical's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Silk Road Medical's Debt-to-Equity falls into.
Silk Road Medical Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Silk Road Medical's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Silk Road Medical's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Silk Road Medical (Silk Road Medical) Business Description
Traded in Other Exchanges
Address
1213 Innsbruck Drive, Sunnyvale, CA, USA, 94089
Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk.
Executives
| Chas Mckhann |
director, officer: Chief Executive Officer |
1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025 |
| Marie L. Jones |
officer: CAO and VP, Finance |
1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089 |
| Lucas W. Buchanan |
officer: Chief Financial Officer |
C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089 |
| Kevin M Klemz |
officer: EVP/Chief Legal Officer/Sec. |
9600 54TH AVENUE NORTH, SUITE 100, PLYMOUTH MN 55442 |
| Andrew S. Davis |
officer: Chief Commercial Officer |
C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089 |
| Erica J. Rogers |
director, officer: President and CEO |
C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089 |
| Elizabeth H Weatherman |
director |
C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017 |
| Richard Ruedy |
officer: EVP Clin & Reg. Affairs and QA |
C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089 |
| Tony M. Chou |
director |
C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089 |
| Tanisha Carino |
director |
C/O ALEXION PHARMACEUTICALS, INC., 121 SEAPORT BOULEVARD, BOSTON MA 02210 |
| Kevin J. Ballinger |
director |
C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234 |
| Rick D Anderson |
director |
3600 N CAPITAL OF TEXAS HWY, SUITE B180, AUSTIN TX 78746 |
| Donald Zurbay |
director |
C/O ST. JUDE MEDICAL, INC., ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN 55117 |
| Warburg Pincus Partners Gp Llc |
10 percent owner |
C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017 |
| Warburg Pincus & Co. |
10 percent owner |
450 LEXINGTON AVENUE, NEW YORK, NY NY 100173147 |
Silk Road Medical (Silk Road Medical) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SILK has been successfully added to your